Gene · 7307
Papers3,382
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
821 to 840 of 3,382
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers. | Cancer Res | 2022 | 36074020 | PubTator, text mining | PubMed |
| Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO. | Leukemia | 2022 | 36071100 | PubTator, text mining | PubMed |
| Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia. | Front Oncol | 2022 | 36059646 | PubTator, text mining | PubMed |
| Suppression of ACE2 SUMOylation protects against SARS-CoV-2 infection through TOLLIP-mediated selective autophagy. | Nat Commun | 2022 | 36057605 | PubTator, text mining | PubMed |
| Spatial heterogeneity and differential treatment response of acute myeloid leukemia and relapsed/refractory extramedullary disease after allogeneic hematopoietic cell transplantation. | Ther Adv Hematol | 2022 | 36050938 | PubTator, text mining | PubMed |
| JMJD family proteins in cancer and inflammation. | Signal Transduct Target Ther | 2022 | 36050314 | PubTator, text mining | PubMed |
| Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms. | Curr Hematol Malig Rep | 2022 | 36048275 | PubTator, text mining | PubMed |
| Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease. | J Hematol Oncol | 2022 | 36045390 | PubTator, text mining | PubMed |
| Impact of a bisphenol A, F, and S mixture and maternal care on the brain transcriptome of rat dams and pups. | Neurotoxicology | 2022 | 36041667 | PubTator, text mining | PubMed |
| Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations. | Elife | 2022 | 36040792 | PubTator, text mining | PubMed |
| Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review. | J Immunother Precis Oncol | 2022 | 36034581 | PubTator, text mining | PubMed |
| Exploring the mechanistic link between SF3B1 mutation and ring sideroblast formation in myelodysplastic syndrome. | Sci Rep | 2022 | 36028755 | PubTator, text mining | PubMed |
| Molecular Pathways in Clonal Hematopoiesis: From the Acquisition of Somatic Mutations to Transformation into Hematologic Neoplasm. | Life (Basel) | 2022 | 36013314 | PubTator, text mining | PubMed |
| Myeloid-Derived Suppressor Cells: New Insights into the Pathogenesis and Therapy of MDS. | J Clin Med | 2022 | 36013147 | PubTator, text mining | PubMed |
| Molecular Threat of Splicing Factor Mutations to Myeloid Malignancies and Potential Therapeutic Modulations. | Biomedicines | 2022 | 36009519 | PubTator, text mining | PubMed |
| Emergent Role of IFITM1/3 towards Splicing Factor (SRSF1) and Antigen-Presenting Molecule (HLA-B) in Cervical Cancer. | Biomolecules | 2022 | 36008984 | PubTator, text mining | PubMed |
| Multi-omics analysis reveals RNA splicing alterations and their biological and clinical implications in lung adenocarcinoma. | Signal Transduct Target Ther | 2022 | 35989380 | PubTator, text mining | PubMed |
| The endogenous HBZ interactome in ATL leukemic cells reveals an unprecedented complexity of host interacting partners involved in RNA splicing. | Front Immunol | 2022 | 35979358 | PubTator, text mining | PubMed |
| Alternative RNA splicing in cancer: what about adult T-cell leukemia? | Front Immunol | 2022 | 35979354 | PubTator, text mining | PubMed |
| Retrospective analysis of somatic mutations and clonal hematopoiesis in astronauts. | Commun Biol | 2022 | 35978153 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7307/papers?page=42